Zhejiang Taimei Medical Technology Co Ltd Class H (HK:2576)
:2576
Want to see HK:2576 full AI Analyst Report?
2576 Stock Chart & Stats
HK$4.20
-HK$0.14(-3.49%)
At close: 4:00 PM EST
HK$4.20
-HK$0.14(-3.49%)
Day’s Range― - ―
52-Week RangeHK$3.28 - HK$5.31
Previous CloseN/A
Volume77.00K
Average Volume (3M)61.29K
Market Cap
HK$2.53B
Enterprise ValueHK$1.70B
Total Cash (Recent Filing)HK$978.70M
Total Debt (Recent Filing)HK$26.29M
Price to Earnings (P/E)―
Beta1.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding200,592,530
10 Day Avg. Volume68,100
30 Day Avg. Volume61,293
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.79
Price to Sales (P/S)4.02
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a sizable equity base provide durable financial flexibility to fund operations and absorb losses while the business scales. This reduces short-term refinancing risk and supports continued investment in product and market development over the next several months.
Large 2025 Revenue ReboundA 278% revenue rebound in 2025 signals meaningful commercial traction or recovery in demand. If sustained, this establishes a scalable revenue base that can drive operating leverage, support margin expansion, and materially improve the path to sustainable profitability.
Improved Gross MarginsA jump to ~42% gross margin indicates improved pricing, mix, or cost control at the gross level. Sustained higher gross margins create durable operating leverage potential and a clearer route to positive operating profit as revenue scales.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow forces reliance on external financing or equity, limiting organic reinvestment. Even with 2025 improvement, ongoing cash burn elevates execution and funding risk until operations become cash-positive.
Still Loss-making At Operating LevelNegative EBIT/EBITDA means core operations are not yet profitable, so the company must either sustain high revenue growth or cut operating costs to reach breakeven. This prolongs dependence on capital and increases risk over the 2–6 month horizon.
Volatile Revenue And Cash MetricsLarge swings in revenue and a ~62% deterioration in free cash flow growth indicate unstable underlying economics. This volatility complicates planning, heightens financing uncertainty, and weakens confidence that recent improvements will persist through multiple quarters.
Zhejiang Taimei Medical Technology Co Ltd Class H News
2576 FAQ
What was Zhejiang Taimei Medical Technology Co Ltd Class H’s price range in the past 12 months?
Zhejiang Taimei Medical Technology Co Ltd Class H lowest stock price was HK$3.28 and its highest was HK$5.31 in the past 12 months.
What is Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap?
Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap is HK$2.53B.
When is Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhejiang Taimei Medical Technology Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Zhejiang Taimei Medical Technology Co Ltd Class H overvalued?
According to Wall Street analysts Zhejiang Taimei Medical Technology Co Ltd Class H’s price is currently Overvalued.
Does Zhejiang Taimei Medical Technology Co Ltd Class H pay dividends?
Zhejiang Taimei Medical Technology Co Ltd Class H does not currently pay dividends.
What is Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate?
Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhejiang Taimei Medical Technology Co Ltd Class H have?
Zhejiang Taimei Medical Technology Co Ltd Class H has 200,592,530 shares outstanding.
What happened to Zhejiang Taimei Medical Technology Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhejiang Taimei Medical Technology Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhejiang Taimei Medical Technology Co Ltd Class H Stock Smart Score
Company Description
Zhejiang Taimei Medical Technology Co Ltd Class H
Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders. It offers software solutions, such as eCooperate, a clinical trial cooperation platform that optimizes clinical research operations management systems, as well as support decision-making with big data technology; eArchives, a clinical trial master file system; eCollect, an electronic data capture system; eCollege, a training management system; eQuality, an electronic quality audit system; eBalance, an interactive Web-based response system; eVisit Patient Reported Outcomes, a solution that enhances the ability of patients to enter data and the accuracy of clinical trial data; eTime, a project man-hour management system; and eImage, a medical image reading system. It also provides hospital software, including eTrial, a phase I ward management system; eSite, a clinical trial management system for GCP sites; GCP-X, an intelligent clinical trial platform; NomenCTMS, a clinical research project management system for GCP sites; eScreening, a subject information management and duplicate checking system; Intelligent Investigator, an initiated clinical trial platform; IIT-EDC, a clinical research data management platform; and Investigator-Initiated Clinical Trial Management System, a project management system. In addition, the company offers pharmacovigilance software solutions, such as eSafety global pharmacovigilance system; eSafety, an intelligent professional information system for pharmacovigilance; and SAE Manager, a safety data communication and management system for clinical trials. Further, it provides marketing software and digital innovation solutions. The company was founded in 2013 and is headquartered in Jiaxing, China.
Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Earnings & Revenues
Technical Analysis
Human Health Holdings Ltd.
―
Vincent Medical Holdings Limited
―
Tycoon Group Holdings Limited
―
China Tian Yuan Healthcare Group Limited
―
UMP Healthcare Holdings Limited
―